EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC) with EGFR activating mutations - real world data

被引：0
|
作者：
Dulloo, Sean [1 ]
Almusarhed, Manar [1 ]
Chen, Ryan [2 ]
Akala, Oyeyemi [1 ]
Varadhan, Balaji [1 ]
Chauhan, Meera [1 ]
Ahmed, Samreen [1 ]
机构：
[1] Univ Hosp Leicester NHS Trust, Leicester Royal Infirm, Leicester, Leics, England
[2] Univ Leicester, Leicester, Leics, England
来源：
LUNG CANCER | 2021年 / 156卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
96
引用
收藏
页码：S40 / S40
页数：1
相关论文
共 50 条
  • [1] Developing of EGFR resistant mutations to Tyrosine Kinase Inhibitors (TKI) in Non-Small Cell Lung Cancer (NSCLC)
    Raez, L. E.
    Baca, Y.
    Nagasaka, M.
    Nieva, J.
    Mandani, H.
    Wanderwalde, A.
    Borghaei, H.
    Naban, C.
    Langer, C.
    Socinsky, M. A.
    Lopes, G.
    Khan, H.
    Wozniak, A.
    Carracedo, C.
    Liu, S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S597 - S597
  • [2] Real world data on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) use in advanced/metastatic non-small cell lung cancer (NSCLC) with EGFR mutations in Singapore
    Chua, B.
    Tan, E. H.
    Lim, D. W-T.
    Ang, M-K.
    Tan, D. S. W.
    Ng, Q-S.
    Kanesvaran, R.
    Jain, A.
    Tan, W-L.
    Toh, C. K.
    Rajasekaran, T.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [3] Multiplicity of EGFR and KRAS Mutations in Non-small Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors
    Benesova, Lucie
    Minarik, Marek
    Jancarikova, Dana
    Belsanova, Barbora
    Pesek, Milos
    [J]. ANTICANCER RESEARCH, 2010, 30 (05) : 1667 - 1671
  • [4] Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
    Wang, Jun
    Wang, Baocheng
    Chu, Huili
    Yao, Yunfeng
    [J]. ONCOTARGETS AND THERAPY, 2016, 9 : 3711 - 3726
  • [5] Elucidating mechanisms of resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC)
    Pao, William
    Miller, Vincent A.
    Kris, Mark G.
    Varmus, Harold E.
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 4 - 4
  • [6] The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
    Rachiglio, Anna Maria
    Fenizia, Francesca
    Piccirillo, Maria Carmela
    Galetta, Domenico
    Crino, Lucio
    Vincenzi, Bruno
    Barletta, Emiddio
    Pinto, Carmine
    Ferrau, Francesco
    Lambiase, Matilde
    Montanino, Agnese
    Roma, Cristin
    Ludovini, Vienna
    Montagna, Elisabetta Sara
    De Luca, Antonella
    Rocco, Gaetano
    Botti, Gerardo
    Perrone, Francesco
    Morabito, Alessandro
    Normanno, Nicola
    [J]. CANCERS, 2019, 11 (03):
  • [7] Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
    Gazdar, A. F.
    [J]. ONCOGENE, 2009, 28 : S24 - S31
  • [8] Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
    A F Gazdar
    [J]. Oncogene, 2009, 28 : S24 - S31
  • [9] Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
    Ahn, H.
    Kim, Y.
    Kim, E. Y.
    Kim, K. W.
    Sung, K. H.
    Cho, E. K.
    Kang, S. M.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [10] EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
    Xiuning Le
    Eric Nadler
    Daniel B. Costa
    John Victor Heymach
    [J]. Targeted Oncology, 2023, 18 : 807 - 817
12345